Aditya Bardia

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 88

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Therapeutic advances in medical oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

The oncologist

Massachusetts General Hospital Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Massachusetts General Hospital Cancer Center

United States

Attending Physician :: Medical Oncology

Publications

Aditya Bardia, Lajos Pusztai, Kathy Albain, Eva Maria Ciruelos, Seock-Ah Im, Dawn Hershman, Kevin Kalinsky, Claudine Isaacs, Delphine Loirat, Laura Testa, Eriko Tokunaga, Jiong Wu, Hannah Dry, William Barlow, Robert Kozarski, Micah Maxwell, Nadia Harbeck, Priyanka Sharma
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic advances in medical oncology 16 (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joo Hyuk Sohn, null null
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (18) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Javier Cortes, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot-Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sebastien, Aditya Bardia
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joo Hyuk Sohn, null null
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Aditya Bardia, Javier Cortes, Francois-Clement Bidard, Patrick Neven, José Angel García-Saenz, Philippe Aftimos, Joyce O'Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia G Kaklamani
Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joo Hyuk Sohn, null null
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (18) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joo Hyuk Sohn, null null
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Seth A Wander, Aditya Bardia
Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joo Hyuk Sohn, null null
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (18) (2024)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Javier Cortes, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot-Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sebastien, Aditya Bardia
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Seth A Wander, Aditya Bardia
Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joo Hyuk Sohn, null null
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (18) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Anne Loeser, Janice S Kim, Jeffrey M Peppercorn, Mark E Burkard, Andrzej Niemierko, Dejan Juric, Kevin M Kalinsky, Hope S Rugo, Lesley Glenn, Christine Hodgdon, Julia Maués, Sheila Johnson, Natalia Padron, Kimberly Parekh, Maryam B Lustberg, Aditya Bardia
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO oncology practice (2024)
Seth A Wander, Aditya Bardia
Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Komal L Jhaveri, Elgene Lim, Rinath M Jeselsohn, Cynthia X Ma, Erika Paige Hamilton, Cynthia Osborne, Manali Bhave, Peter A Kaufman, J Thaddeus Beck, Luis Manso Sanchez, Ritesh Parajuli, Hwei-Chung Wang, Jessica J Tao, Seock-Ah Im, Kathleen K Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean-Yves Pierga, Yen-Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joo Hyuk Sohn, Sung-Bae Kim, Cristina Saura, Aditya Bardia, Sarah L Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian M Smyth, Muralidhar Beeram
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Anne Loeser, Janice S Kim, Jeffrey M Peppercorn, Mark E Burkard, Andrzej Niemierko, Dejan Juric, Kevin M Kalinsky, Hope S Rugo, Lesley Glenn, Christine Hodgdon, Julia Maués, Sheila Johnson, Natalia Padron, Kimberly Parekh, Maryam B Lustberg, Aditya Bardia
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO oncology practice 20 (7) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Aditya Bardia, Giuseppe Viale
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Targeted oncology 18 (3) (2023)
Aditya Bardia, Giuseppe Viale
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Targeted oncology 18 (3) (2023)
Komal L Jhaveri, Meritxell Bellet-Ezquerra, Nicholas C Turner, Sherene Loi, Aditya Bardia, Valentina Boni, Joo Hyuk Sohn, Tomas G Neilan, Rafael Villanueva-Vázquez, Peter Kabos, Laura García Estévez, Elena Lopez-Miranda, José Alejandro Pérez-Fidalgo, Jose Manuel Perez-Garcia, Jiajie Yu, Jill Fredrickson, Heather M Moore, Ching-Wei Chang, John W Bond, Jennifer Eng-Wong, Mary R Gates, Elgene Lim
Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Shannon McLaughlin, Erika Nakajima, Yael Bar, Jennifer A Hutchinson, Jennifer Shin, Beverly Moy, Steven J Isakoff, Aditya Bardia, Irene Kuter, Laura M Spring
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. Therapeutic advances in medical oncology 15 (2023)
Shannon McLaughlin, Erika Nakajima, Yael Bar, Jennifer A Hutchinson, Jennifer Shin, Beverly Moy, Steven J Isakoff, Aditya Bardia, Irene Kuter, Laura M Spring
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. Therapeutic advances in medical oncology 15 (2023)
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S L Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Avinash Kambadakone, Laura M Spring, Douglas S Micalizzi, Maristela L Onozato, Dante Che, Utthara Nayar, Adam M Brufsky, Kevin M Kalinsky, Cynthia X Ma, Joyce O'Shaughnessy, Hyo S Han, Anthony J Iafrate, Lianne Y Ryan, Dejan Juric, Beverly Moy, Leif W Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A Haber, Aditya Bardia, Seth A Wander
A Gene Panel Associated With Abemaciclib Utility in ESR1 -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO precision oncology 7 (2023)
Aditya Bardia, Giuseppe Viale
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Targeted oncology (2023)
Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Giancarlo Feliciello, Katherine K Clifton, Leslie A Bucheit, Whitney L Hensing, Ami N Shah, Tania Pivetta, Charles S Dai, Paolo D'Amico, Firas H Wehbe, Arielle J Medford, Seth A Wander, William J Gradishar, Amir Behdad, Cynthia X Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO precision oncology 7 (2023)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist 28 (2) (2023)
Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. The oncologist (2023)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist 28 (2) (2023)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier, Allison M Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi, Xin Yuan, Janice S Kim, Haley Ellis, Alkistis Papatheodoridi, Hakan Gunaydin, Brian P Danysh, Laxmi Parida, Ioannis Sanidas, Yongli Ji, Kayao Lau, Gerburg M Wulf, Aditya Bardia, Laura M Spring, Steven Jay Isakoff, Jochen K Lennerz, Levi Pierce, Ermira Pazolli, Gad A Getz, Ryan B Corcoran, Dejan Juric
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer discovery (2023)
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S L Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Avinash Kambadakone, Laura M Spring, Douglas S Micalizzi, Maristela L Onozato, Dante Che, Utthara Nayar, Adam M Brufsky, Kevin M Kalinsky, Cynthia X Ma, Joyce O'Shaughnessy, Hyo S Han, Anthony J Iafrate, Lianne Y Ryan, Dejan Juric, Beverly Moy, Leif W Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A Haber, Aditya Bardia, Seth A Wander
A Gene Panel Associated With Abemaciclib Utility in ESR1 -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO precision oncology 7 (2023)
Aditya Bardia, Giuseppe Viale
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Targeted oncology 18 (3) (2023)
Dennis J Slamon, Peter A Fasching, Sara Alsterlind Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos Henrique Barrios, Aditya Bardia, Seock-Ah Im, Denise A Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N Hortobagyi
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic advances in medical oncology 15 (2023)
Laura M Spring, Lindsey Mortensen, Elizabeth Abraham, Jennifer Keenan, Arielle J Medford, Annie Ma, Sarah Padden, Elyssa N Denault, Lianne Ryan, A John Iafrate, Jochen K Lennerz, Ephraim P Hochberg, Seth A Wander, Beverly Moy, Steven Jay Isakoff, Dejan Juric, Kimberly A Brennan, Deborah E Smith, Barbara Civiello, Therese Marie Mulvey, Amy H Comander, Leif W Ellisen, Joel H Schwartz, Aditya Bardia
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration. JCO oncology practice (2023)
Aditya Bardia, Giuseppe Viale
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Targeted oncology (2023)
Aditya Bardia, Giuseppe Viale
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Targeted oncology 18 (3) (2023)
Whitney L Hensing, Lorenzo Gerratana, Katherine K Clifton, Arielle J Medford, Marko Velimirovic, Ami N Shah, Paolo D'Amico, Giancarlo Feliciello, Qiang Zhang, Charles S Dai, Elyssa N Denault, Nusayba A Bagegni, Mateusz Opyrchal, Foluso O Ademuyiwa, Ron Bose, Amir Behdad, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli, Andrew A Davis
Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Pernas, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock-Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laurentiis, Noelia Martínez Jañez, Barbara Adamo, Keun Seok Lee, Kyung Hae Jung, Gabor Rubovszky, Ling-Ming Tseng, Yen-Shen Lu, Yuan Yuan, Micah J Maxwell, Vincent Haddad, Sabrina S Khan, Hope S Rugo, Barbara Pistilli
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future oncology (London, England) (2023)
Hope S Rugo, Victoria Harmer, Joyce O'Shaughnessy, Komal Jhaveri, Sara M Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A Fasching
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Therapeutic advances in medical oncology 15 (2023)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist 28 (2) (2023)
Arielle J Medford, Lauren Oshry, Baris Boyraz, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Charles S Dai, Tasos Gogakos, Jennifer C Keenan, Rachel H Occhiogrosso, Phoebe Ryan, Jochen K Lennerz, Laura M Spring, Beverly Moy, Leif W Ellisen, Aditya Bardia
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic advances in medical oncology 15 (2023)
Arielle J Medford, Beverly Moy, Laura M Spring, Sara Alsterlind Hurvitz, Nicholas C Turner, Aditya Bardia
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Arielle J Medford, Lauren Oshry, Baris Boyraz, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Charles S Dai, Tasos Gogakos, Jennifer C Keenan, Rachel H Occhiogrosso, Phoebe Ryan, Jochen K Lennerz, Laura M Spring, Beverly Moy, Leif W Ellisen, Aditya Bardia
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic advances in medical oncology 15 (2023)
Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. The oncologist (2023)
Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Giancarlo Feliciello, Katherine K Clifton, Leslie A Bucheit, Whitney L Hensing, Ami N Shah, Tania Pivetta, Charles S Dai, Paolo D'Amico, Firas H Wehbe, Arielle J Medford, Seth A Wander, William J Gradishar, Amir Behdad, Cynthia X Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO precision oncology 7 (2023)
Hope S Rugo, Victoria Harmer, Joyce O'Shaughnessy, Komal Jhaveri, Sara M Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A Fasching
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Therapeutic advances in medical oncology 15 (2023)
Sarat Chandarlapaty, Maura N Dickler, José Alejandro Pérez-Fidalgo, Rafael Villanueva-Vázquez, Jennifer M Giltnane, Mary R Gates, Ching-Wei Chang, Sravanthi Cheeti, Jill Fredrickson, Xiaojing Wang, Ann Collier, Heather M Moore, Ciara Metcalfe, Jennifer Lauchle, Eric W Humke, Aditya Bardia
An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Maria I Stamou, Christopher T Chen, Seth A Wander, Jeffrey G Supko, Dejan Juric, Aditya Bardia, Deborah J Wexler
Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. JCO precision oncology 6 (2022)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist (2022)
Elyssa Denault, Erika Nakajima, Vivek Naranbhai, Jennifer A Hutchinson, Lindsey Mortensen, Elizabeth Neihoff, Caroline Barabell, Amy Comander, Dejan Juric, Irene Kuter, Theresa Mulvey, Jeffrey Peppercorn, Aron S Rosenstock, Jennifer Shin, Neelima Vidula, Seth A Wander, Beverly Moy, Leif W Ellisen, Steven J Isakoff, A John Iafrate, Justin F Gainor, Aditya Bardia, Laura M Spring
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. Therapeutic advances in medical oncology 14 (2022)
Hope S Rugo, Aditya Bardia, Frederic Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos Gil, Florence Dalenc, Patricia Gómez Pardo, Komal L Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M Tolaney
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (29) (2022)
Aditya Bardia, Javier Cortes, Sara A Hurvitz, Suzette Delaloge, Hiroji Iwata, Zhi-Ming Shao, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Joyce O'Shaughnessy
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. Therapeutic advances in medical oncology 14 (2022)
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K Harnden, Hung T Khong, Judit Kocsis, Florence Dalenc, Patrick M Dillon, Sunil Babu, Simon H Waters, Ines Deleu, José A García Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G Conlan, Aditya Bardia
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (28) (2022)
Maxwell R Lloyd, Seth A Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Therapeutic advances in medical oncology 14 (2022)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 8 (1) (2022)
Aditya Bardia, Kathleen Harnden, Lauren Mauro, Angela Pennisi, Melissa Armitage, Hatem Soliman
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. The oncologist 27 (8) (2022)
Aditya Bardia, Ingrid Mayer, Eric Winer, Hannah M Linden, Cynthia X Ma, Barbara A Parker, Meritxell Bellet, Carlos L Arteaga, Sravanthi Cheeti, Mary Gates, Ching-Wei Chang, Jill Fredrickson, Jill M Spoerke, Heather M Moore, Jennifer Giltnane, Lori S Friedman, Edna Chow Maneval, Iris Chan, Komal Jhaveri
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer. Breast cancer research and treatment (2022)
Francois-Clement Bidard, Virginia G Kaklamani, Aditya Bardia
Reply to R. Nishihara et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Aditya Bardia, Sarat Chandarlapaty, Hannah M Linden, Gary A Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nature communications 13 (1) (2022)
Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jessop, Alexander A Farahani, Mari Mino-Kenudson, Jill Allen, Lipika Goyal, Aparna Parikh, Joseph Misdraji, Ganesh Shankar, Justin T Jordan, Maria Martinez-Lage, Matthew Frosch, Timothy Graubert, Amir T Fathi, Gabriela S Hobbs, Robert P Hasserjian, Noopur Raje, Jeremy Abramson, Joel H Schwartz, Ryan J Sullivan, David Michael Miller, Mai P Hoang, Steven Isakoff, Amy Ly, Sara Bouberhan, Jaclyn Watkins, Esther Oliva, Lori J Wirth, Peter M Sadow, William Faquin, Gregory M Cote, Yin P Hung, Xin Gao, Chin-Lee Wu, Salil Garg, Miguel Rivera, Long P Le, A John Iafrate, Dejan Juric, Ephraim P Hochberg, Jeffrey Clark, Aditya Bardia, Jochen K Lennerz
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. The oncologist 27 (11) (2022)
Aditya Bardia, Virginia G Kaklamani, Sharon Wilks, Amy Weise, Donald Richards, Wael Harb, Cynthia Osborne, Robert Wesolowski, Meghan Karuturi, Paul Conkling, Rebecca G Bagley, Yamei Wang, Maureen G Conlan, Peter Kabos
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)
Priscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, Nancy Wang, Justine V Cohen, Ugonma Chukwueke, Deborah Anne Forst, April Eichler, Beth Overmoyer, Nancy U Lin, Wendy Y Chen, Aditya Bardia, Dejan Juric, Ibiayi Dagogo-Jack, Michael D White, Jorg Dietrich, Naema Nayyar, Albert E Kim, Christopher Alvarez-Breckenridge, Maura Mahar, Joana Liliana Mora, Brian V Nahed, Pamela S Jones, Helen A Shih, Elizabeth R Gerstner, Anita Giobbie-Hurder, Scott L Carter, Kevin Oh, Daniel P Cahill, Ryan J Sullivan
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nature communications 12 (1) (2021)
Laura M Spring, Erika Nakajima, Jennifer Hutchinson, Elene Viscosi, Gayle Blouin, Colin Weekes, Hope Rugo, Beverly Moy, Aditya Bardia
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. The oncologist 26 (10) (2021)
Tanmoy Saha, Chinmayee Dash, Ruparoshni Jayabalan, Sachin Khiste, Arpita Kulkarni, Kiran Kurmi, Jayanta Mondal, Pradip K Majumder, Aditya Bardia, Hae Lin Jang, Shiladitya Sengupta
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. Nature nanotechnology (2021)
Laura M Spring, Shealagh L Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J Isakoff, Erica L Mayer, Beverly Moy, Jeffrey G Supko, Sara M Tolaney, Aditya Bardia
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ breast cancer 7 (1) (2021)
Lindsey Mortensen, Zehra Ordulu, Ibiayi Dagogo-Jack, Veerle Bossuyt, Loren Winters, Alphonse Taghian, Barbara L Smith, Leif W Ellisen, Lesli A Kiedrowski, Jochen K Lennerz, Aditya Bardia, Laura M Spring
Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. The oncologist 26 (10) (2021)
Howard A Burris, Arlene Chan, Aditya Bardia, J Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debasish Tripathy, Seock-Ah Im, Stephen Chia, Francisco J Esteva, Lowell Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez Lorenc, Denise A Yardley
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British journal of cancer 125 (5) (2021)
Vivek Naranbhai, Claire A Pernat, Alexander Gavralidis, Kerri J St Denis, Evan C Lam, Laura M Spring, Steven Jay Isakoff, Jocelyn R Farmer, Leyre Zubiri, Gabriela S Hobbs, Joan How, Andrew M Brunner, Amir T Fathi, Jennifer L Peterson, Mustafa Sakhi, Grace Hambelton, Elyssa N Denault, Lindsey J Mortensen, Lailoo A Perriello, Marissa N Bruno, Brittany Y Bertaux, Aleigha R Lawless, Monica A Jackson, Elizabeth Niehoff, Caroline Barabell, Christian N Nambu, Erika Nakajima, Trenton Reinicke, Cynthia Bowes, Cristhian J Berrios-Mairena, Onosereme Ofoman, Grace E Kirkpatrick, Julia C Thierauf, Kerry Lynn Reynolds, Henning Willers, Wilfredo-Garcia Beltran, Anand S Dighe, Rebecca R Saff, Kimberly G Blumenthal, Ryan J Sullivan, Yi-Bin Chen, Arthur Y Kim, Aditya Bardia, Alejandro B Balazs, A John Iafrate, Justin F Gainor
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Aiko Nagayama, Neelima Vidula, Leif Ellisen, Aditya Bardia
Novel antibody-drug conjugates for triple negative breast cancer. Therapeutic advances in medical oncology 12 (2020)
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L Blackwell, Lisa A Carey, Joel R Eisner, Edwina S Baskin-Bey, Tiffany A Traina
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast cancer research and treatment 171 (1) (2018)

Aditya Bardia.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Aditya Bardia